


Sheridan Macy and Charlotte Arneson
FIRE
After studying engineering at Rutgers, Rami Elghandour began chasing a problem that has haunted medicine for decades — how to teach the body to kill cancer cells without destroying itself in the process. This spring, his biotechnology company, Arcellx, unveiled a treatment that moves the science closer to that goal than ever before. In conference halls and investor calls, the reaction bordered on astonishment. Last month, Gilead Sciences bought Arcellx in a deal valued at $7.8 billion.
So it was no surprise when Rutgers invited Elghandour to give the engineering school’s graduation speech this year. But the speech was promptly canceled after students (about five of them, Elghandour estimates) complained about remarks he’d made on social media.
Leave a comment
Comments will be approved before showing up.